公开(公告)号：WO2015031996A1

公开(公告)日：2015-03-12

申请号：PCT/CA2014/050841

申请日：2014-09-05

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KAIN, Kevin ,  LILES, W. Conrad ,  ERDMAN, Laura ,  CONROY, Andrea

IPC: G01N33/543 ,  C40B30/04 ,  C40B40/10 ,  G01N33/48

CPC classification number: G01N33/6842 ,  G01N2800/50 ,  G01N2800/52 ,  Y02A50/53 ,  Y02A50/56 ,  Y02A50/58

Abstract: The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

Abstract translation: 本发明涉及使用新的生物标志物和生物标志物组合，其可用于早期确定个体对疾病的危及生命和/或威胁生命的反应和/或预测所述疾病的结果。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于确定个体对疾病的关键和/或威胁生命的反应。 在一些实施方案中，生物标志物和生物标志物组合是不可知的，并且独立于疾病的原因或性质的预先识别和/或确定。 在一些实施方案中，生物标志物和生物标志物组合可用于选择治疗和/或监测具有严重疾病的个体的治疗干预的有效性。

公开(公告)号：WO2013127000A1

公开(公告)日：2013-09-06

申请号：PCT/CA2013/000192

申请日：2013-02-27

Applicant: UNIVERSITY HEALTH NETWORK (UHN)

Inventor： KAIN, Kevin ,  LILES, Conrad, W. ,  ERDMAN, Laura ,  CONROY, Andrea

IPC: G01N33/68 ,  G01N33/53

CPC classification number: G01N33/56983 ,  G01N33/53 ,  G01N33/569 ,  G01N33/56905 ,  G01N33/56916 ,  G01N33/56944 ,  G01N33/68 ,  G01N33/6893 ,  Y02A50/53 ,  Y02A50/56 ,  Y02A50/58

Abstract: The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to monitor the effectiveness of treatment interventions for an individual who has a critical illness.

Abstract translation: 本发明涉及使用新的生物标志物和生物标志物组合，其可用于早期确定个体对疾病的危及生命和/或威胁生命的反应和/或预测所述疾病的结果。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于确定个体对疾病的关键和/或威胁生命的反应。 在一些实施方案中，生物标志物和生物标志物组合是不可知的，并且独立于疾病的原因或性质的预先识别和/或确定。 在一些实施方案中，生物标志物和生物标志物组合可用于监测具有严重疾病的个体的治疗干预的有效性。

公开(公告)号：WO2012016333A1

公开(公告)日：2012-02-09

申请号：PCT/CA2011/000894

申请日：2011-08-05

Applicant: UNIVERSITY HEALTH NETWORK ,  KAIN, Kevin C. ,  LILES, W. Conrad ,  ERDMAN, Laura ,  CONROY, Andrea

Inventor： KAIN, Kevin C. ,  LILES, W. Conrad ,  ERDMAN, Laura ,  CONROY, Andrea

IPC: G01N33/48 ,  G01N33/53

CPC classification number: G01N33/56905 ,  G01N2333/924 ,  G01N2800/50 ,  G01N2800/56 ,  Y02A50/58

Abstract: There is provided a method of identifying a subject having, or at risk of developing, severe or fatal malaria. Embodiments include determining the level of one or more biomarkers selected from angiopoietin-1 (ANG-1), angiopoietin-2 (ANG-2), von Willebrand factor (VWF), von Willebrand factor propeptide (VWFpp), soluble P-selectin, soluble ICAM-1 (sICAM-1), soluble endoglin, soluble FLT-1 (sFLT-1), soluble Tie-2 (sTie-2), C-Reactive Protein (CRP), procalicitonin (PCT), IP-10, chitinase-3-like-1 (CHI3L1), VEGF and Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in a test sample from a subject. Levels of the one or more biomarkers in the test sample are compared to a control sample, wherein a difference between the level of the one or more biomarkers in the test sample and the control sample indicates that the subject has, or is at risk of developing, severe or fatal malaria.

Abstract translation: 提供了一种识别具有或有发展为严重或致命疟疾风险的受试者的方法。 实施方案包括确定选自血管生成素-1（ANG-1），血管生成素-2（ANG-2），血管性血友病因子（VWF），血管性血友病因子前肽（VWFpp），可溶性P-选择蛋白， 可溶性内皮糖蛋白，可溶性FLT-1（sFLT-1），可溶性Tie-2（sTie-2），C-反应蛋白（CRP），普乐质素（PCT），IP-10， 来自受试者的测试样品中表达于骨髓细胞-1（TREM-1）的几丁质酶-3-样-1（CHI3L1），VEGF和触发受体。 将测试样品中的一种或多种生物标志物的水平与对照样品进行比较，其中测试样品中的一种或多种生物标志物的水平与对照样品之间的差异表明受试者具有或有发展的风险 ，严重或致命的疟疾。

公开(公告)号：EP3042200A1

公开(公告)日：2016-07-13

申请号：EP14842541.6

申请日：2014-09-05

Applicant: University Health Network

Inventor： KAIN, Kevin ,  LILES, W. Conrad ,  ERDMAN, Laura ,  CONROY, Andrea

IPC: G01N33/543 ,  C40B30/04 ,  C40B40/10 ,  G01N33/48

CPC classification number: G01N33/6842 ,  G01N2800/50 ,  G01N2800/52 ,  Y02A50/53 ,  Y02A50/56 ,  Y02A50/58

Abstract: The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

Abstract translation: 本发明涉及使用新的生物标志物，并且具有在早期确定患病个体的关键和/或威胁生命的响应和/或在预测所述疾病的预后的生物标记物实用性的组合。 本发明的生物标志物的生物标志物和组合的产物的表达水平的测量在制备疾病个体的关键和/或威胁生命的响应的确定效用。 在一些实施方案中，生物标志和生物标志物组合是不可知的，并且独立的疾病的原因或性质的预识别和/或确定。 在一些实施方案中，生物标记和生物标志物组合可用于选择治疗和/或监测治疗干预对在个体谁具有重大疾病的有效性。

公开(公告)号：EP2820427A1

公开(公告)日：2015-01-07

申请号：EP13755922.5

申请日：2013-02-27

Applicant: University Health Network (UHN)

Inventor： KAIN, Kevin ,  LILES, Conrad, W. ,  ERDMAN, Laura ,  CONROY, Andrea

IPC: G01N33/68 ,  G01N33/53

CPC classification number: G01N33/56983 ,  G01N33/53 ,  G01N33/569 ,  G01N33/56905 ,  G01N33/56916 ,  G01N33/56944 ,  G01N33/68 ,  G01N33/6893 ,  Y02A50/53 ,  Y02A50/56 ,  Y02A50/58

Abstract: The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

Abstract translation: 本发明涉及新型生物标志物和生物标志物组合的应用，其用于早期确定个体对疾病的危急和/或危及生命的反应和/或预测所述疾病的结果。 本发明的生物标志物和生物标志物组合的产物表达水平的测量可用于确定个体对疾病的危急和/或危及生命的反应。 在一些实施方案中，生物标志物和生物标志物组合是不可知的并且独立于疾病的原因或性质的预先识别和/或确定。 在一些实施方案中，生物标志物和生物标志物组合可用于监测治疗干预对患有严重疾病的个体的有效性。